A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS) Meeting Abstract


Authors: Rosenbaum, E.; Qin, L. X.; Thornton, K. A.; Movva, S.; Nacev, B. A.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; Kelly, C. M.; Chan, J. E.; Martindale, M.; Adamson, T.; McKennan, O. R.; Erinjeri, J. P.; Lefkowitz, R. A.; Tap, W. D.; D'Angelo, S. P.
Abstract Title: A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS)
Meeting Title: 2022 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 40
Issue: 16 Suppl.
Meeting Dates: 2022 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2022-06-01
Language: English
ACCESSION: WOS:000863680300358
PROVIDER: wos
DOI: 10.1200/JCO.2022.40.16_suppl.11516
Notes: Meeting Abstract: 11516 -- Meeting also held virtually -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ping Chi
    175 Chi
  2. Li-Xuan Qin
    194 Qin
  3. Mary Louise Keohan
    126 Keohan
  4. Mrinal M Gounder
    230 Gounder
  5. Sandra Pierina D'Angelo
    255 D'Angelo
  6. Joseph Patrick Erinjeri
    204 Erinjeri
  7. Mark Andrew Dickson
    172 Dickson
  8. William Douglas Tap
    378 Tap
  9. Ciara Marie Kelly
    92 Kelly
  10. Benjamin Alexander Nacev
    30 Nacev
  11. Jason Earl Chan
    31 Chan
  12. Sujana Movva
    48 Movva
  13. Travis Edward Adamson
    10 Adamson
  14. Viswatej Avutu
    35 Avutu